×
About 1,888,078 results

WFH Guidelines for the Management of Hemophilia, 3rd edition
https://onlinelibrary.wiley.com/doi/10.1111/hae.14046
Haemophilia

Aug 3rd, 2020 - This new edition of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia comes at an exciting time in the evolution of the diagnosis and treatment of this condition. Since the publication of the second edition in 2012, tremendous advances have been made in several aspects of the management of hemophilia. These include genetic assessment as well as therapy with ma...

Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis
https://jamanetwork.com/journals/jama/article-abstract/2766163
JAMA

May 19th, 2020 - In this meta-analysis that included 12 trials with 92 135 participants for the primary outcome measure, blood pressure lowering with antihypertensive agents, compared with control, was associated with the development of a composite dementia or cognitive impairment outcome in 7.0% vs 7.5% of patients over a mean trial follow-up of 4.1 years, a difference that was statistically significant.

Dr. Lillian L. Siu Honored With 2020 International Women Who Conquer Cancer Mentorship Award
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200112/full/

May 6th, 2020 - Lillian L. Siu, MD, FRCPC, FASCO, of the Princess Margaret Cancer Centre, in Canada, has been chosen as the recipient of the 2020 International Women Who Conquer Cancer Mentorship Award. Dr. Sui is the director of the Phase I Program, co-director of the Bras and Family Drug Development Program, and clinical lead for the Tumor Immunotherapy Program. She also holds the BMO Chair in Precision Geno...

Metabotropic Glutamate Receptors for Parkinson's Disease Therapy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703788/
Parkinson's Disease;

May 29th, 2013 - Excessive glutamatergic signalling within the basal ganglia is implicated in the progression of Parkinson's disease (PD) and inthe emergence of dyskinesia associated with long-term treatment with L-DOPA. There is considerable research focus on the discovery and development of compounds that modulate glutamatergic signalling via glutamate receptors, as treatments for PD and L-DOPA-induced dyskin...

Ocular changes in patients with psoriasis
https://www.sciencedirect.com/science/article/abs/pii/S0738081X19301403?via=ihub
Clinics in Dermatology; Demerdjieva Z

Dec 1st, 2019 - Eye involvement in psoriasis is little known to many dermatologists, although psoriasis has been acknowledged as a systemic disease for decades. The ophthalmic complications of psoriasis are numerous and can affect almost any part of the eye. The most common ocular changes in patients with psoriasis, including blepharitis, conjunctivitis, keratitis, iridocyclitis, UV-induced cataracts, uveitis,...

Levodopa‐induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600052/
Postgraduate Medical Journal;

Jun 5th, 2007 - Levodopa is the most effective drug for treating Parkinson's disease. However, long‐term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa‐induced dyskinesias (LID). The underlying mechanisms f...

The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations
https://www.tandfonline.com/doi/abs/10.1517/14656566.7.10.1399?src=recsys&journalCode=ieop20
Expert Opinion on Pharmacotherapy;

Jun 29th, 2006 - Levodopa is the most efficacious treatment in the management of Parkinson’s disease. Unfortunately, chronic use of traditional levodopa/dopa decarboxylase inhibitor formulations is associated with the development of complications, such as wearing-off and dyskinesia. In an attempt to avoid these complications, some physicians delay the introduction of levodopa or employ levodopa-sparing strategi...

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
https://doi.org/10.1002/art.41752
Arthritis & Rheumatology (Hoboken, N.J.); Fraenkel L, Bathon JM et. al.

Jun 9th, 2021 - To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising c...

National Institute of Biomedical Imaging and Bioengineering (NIBIB)
https://www.nibib.nih.gov/

The mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences to advance basic research and medical care.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
https://www.nichd.nih.gov/

NICHD leads research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all.

Diagnostic Prediction Model for Levodopa-Induced Dyskinesia in Parkinson's Disease
https://www.scielo.br/pdf/anp/v78n4/1678-4227-anp-0004-282x20190191.pdf

There are currently no methods to predict the development of levodopa-induced dyskinesia (LID), a frequent complication of Parkinson's disease (PD) treatment. Clinical predictors and single nucleotide polymorphisms (SNP) have been associated to LID in PD.

COVID-19 and medical education
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30226-7/fulltext
The Lancet Infectious Diseases;

The coronavirus disease 2019 (COVID-19) outbreak has rapidly transitioned into a worldwide pandemic. This development has had serious implications for public institutions and raises particular questions for medical schools. Frequent rotations between departments and hospitals make medical students potential vectors for COVID-19. Equally, as trainee doctors we stand to learn a tremendous amount ...

Coronavirus Q&A: Accelerating Therapies and Vaccines
https://www.youtube.com/watch?v=8asnNFnG-8o

US National Institutes of Health (NIH) Director Francis S. Collins, MD, discusses the agency’s new initiative to collaborate with other agencies and industry to accelerate development and testing of COVID-19 treatments and vaccines.

Delirium in Older Persons
http://www.nytimes.com/packages/flash/health/pdf/Delirium.pdf
The New England Journal of Medicine;

Delirium, an acute decline in attention and cognition, is a common, life-threatening, and potentially preventable clinical syndrome among persons who are 65 years of age or older. The development of delirium often initiates a cascade of events culminating in the loss of independence, an increased risk of morbidity and mortality, and increased health care costs.1-6 Delirium in hospitalized ol...

COVID-19 Treatment & Vaccine Tracker
https://covid-19tracker.milkeninstitute.org/

FasterCures, a center of the Milken Institute, is currently tracking the development of treatments and vaccines for COVID-19 (coronavirus). This tracker contains an aggregation of publicly-available information from validated sources.

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
https://pubs.acs.org/doi/pdf/10.1021/acscentsci.0c00272

Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vacc...

CDA Position Statement on Coronavirus (COVID-19) Pandemic
https://www.copper.org/applications/antimicrobial/COVID-19.html

In response to the COVID-19 pandemic, Copper Development Association (CDA) developed the following position statement to address an influx of inquiries from the media and external stakeholders.

FDA and global partners to analyze coronavirus samples
https://www.fda.gov/emergency-preparedness-and-response/mcm-regulatory-science/fda-and-global-partners-analyze-coronavirus-samples

The emergence of SARS-CoV-2 in 2019 and the associated COVID-19 pandemic, and prior SARS-CoV and MERS-CoV outbreaks, demonstrate the significant threat posed by coronaviruses. Since there are currently no licensed therapeutics or vaccines to prevent or treat infections from these specific viruses or coronaviruses in general, there is an urgent need to support development and evaluation of relev...

The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis
https://www.medrxiv.org/content/10.1101/2020.05.31.20114991v1.full.pdf

Respiratory failure is a key feature of severe Covid-19 and a critical driver of mortality, but for reasons poorly defined affects less than 10% of SARS-CoV-2 infected patients. Methods. We included 1,980 patients with Covid-19 respiratory failure at seven centers in the Italian and Spanish epicenters of the SARS-CoV-2 pandemic in Europe (Milan, Monza, Madrid, San Sebastian and Barcelona) for a...

Clinical Aspects and Management of Levodopa-Induced Dyskinesia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372050/
Parkinson's Disease;

In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias. Strategies to delay or to reduce dyskinesias are based on the change of levodopa dosing or the early use of dopamine agonists. Dopamine agonists with different pharmacological profile a...